Everything below concerns IGF-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
=== Narratives === Œuvres (P.O.L, 2002). Works, trans. Jan Steyn (Dalkey Archive, 2014) Journal (P.O.L, 2004). Newspaper, trans. Jan Steyn and Caite Dolan-Leach (Dalkey Archive, 2015) Autoportrait (P.O.L, 2005). Autoportrait, trans. Lorin Stein (Dalkey Archive, 2012) Suicide (P.O.L, 2008). Suicide, trans. Jan Steyn (Dalkey Archive, 2011)
== Death == Despite initially being given only 30 days to live when learning about his HIV status, Woodroof lived seven more years following his diagnosis before dying on September 12, 1992, from pneumonia brought on by AIDS. He is buried in Restland Memorial Park.
=== October === October 1 The US imposes new sanctions on Iran, targeting rail, automotive, manufacturing, and steel sectors, as well as overseas suppliers, saying that the goal is to economically isolate the Iranian government. The US military starts sending about 9,000 soldiers to the Middle East on naval ships, such as the USS Makin Island amphibious readiness group and the USS Theodore Roosevelt carrier strike group. October 2 The US imposes sanctions on Hamas' financing network, which includes two French-based funds. Alabama state representative Brett Easterbrook is arrested on charges of first-degree human trafficking and prostitution as part of a sting. At least a dozen other men are arrested. October 3 – Trump establishes a task force to examine the risks and opportunities of AI and recommend what role the federal government should play in overseeing the technology without compromising competitiveness with China. October 4 The State Department announces that the US "kicked out" two members of the Iranian delegation who attended the recent United Nations General Assembly after they ignored an order to leave the country long after the General Assembly had ended. Trump withdraws all US bombers from RAF Fairford, a British air base targeted by an attack that the UK linked to the Iranian government, due to urgent concerns about a potentially complex drone attack ordered by the IRGC as part of a plot to target the aircraft and kill American soldiers at RAF Fairford, which is loosely modeled after Ukraine's Operation Spiderweb.
Sources: en.wikipedia.org
== Uses == Cell-free synthetic pathway biotransformation biosystems are proposed as a new low-cost biomanufacturing platform compared to microbial fermentation used for thousands of years. Cell-free biosystems have several advantages suitable in industrial applications:
Smuts informed the General Assembly that it had already been so thoroughly incorporated with South Africa a UN-sanctioned annexation was no more than a necessary formality. The Smuts delegation's request for the termination of the mandate and permission to annex South West Africa was not well received by the General Assembly. Five other countries, including three major colonial powers, had agreed to place their mandates under the trusteeship of the UN, at least in principle; South Africa alone refused. Most delegates insisted it was undesirable to endorse the annexation of a mandated territory, especially when all of the others had entered trusteeship. Thirty-seven member states voted to block a South African annexation of South West Africa; nine abstained. In Pretoria, right-wing politicians reacted with outrage at what they perceived as unwarranted UN interference in the South West Africa affair. The National Party dismissed the UN as unfit to meddle with South Africa's policies or discuss its administration of the mandate. One National Party speaker, Eric Louw, demanded that South West Africa be annexed unilaterally. During the South African general election, 1948, the National Party was swept into power, newly appointed Prime Minister Daniel Malan prepared to adopt a more aggressive stance concerning annexation, and Louw was named ambassador to the UN. During an address in Windhoek, Malan reiterated his party's position that South Africa would annex the mandate before surrendering it to an international trusteeship.
Researchers at BI discovered that using a buty-2-nyl group resulted in a potent candidate, called BI-1356 (Figure 10). In 2008 BI-1356 was undergoing phase III clinical trials; it was released as linagliptin in May 2011. X-ray crystallography has shown that that xanthine type binds the DPP-4 complex in a different way than other inhibitors: 1. The amino group also interacts with the Glu205, Glu206 and Tyr662 2. The buty-2-nyl group occupies the S1-pocket 3. The uracil group undergoes a π-stacking interaction with the Tyr547 residue 4. The quinazoline group undergoes a π-stacking interaction with the Trp629 residue
=== Use in traditional medicine === In modern South Korea, S. mutilans and other Scolopendra species are used in Korean traditional medicine. The centipedes are used whole to treat various medical issues, including joint problems (which is its major use), alopecia areata, stroke, convulsions, lymphangitis, lumps or masses, neoplasm, poisonous tumours, carbuncles, and snake bites. These centipedes were considered one of the most prescribed, medically important, and expensive insect/arthropod drugs in Korean traditional medicine. They are frequently prescribed alone, despite arthropod drugs are usually prescribed with a mix of other medicinal materials for desired effects. In China, S. mutilans is the only centipede species registered for clinical application by the Pharmacopeia of the People's Republic of China. Despite being the only species listed, other species of centipedes, including S. mojiangica, S. multidens, and S. negrocapitis, were also regularly used as substitutes in clinical practice.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.